ArticleBiochemical and biophysical research communications2005
Characterization and application of monoclonal antibodies against N protein of SARS-coronavirus.
Article in Biochemical and biophysical research communications, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Structural basis of a human antibody targeting SARS-CoV-2 nucleocapsid protein dimerization domain and interfering with RNA-binding.Communications biology · 2025Article
- Colorimetric and Raman dual-mode lateral flow immunoassay detection of SARS-CoV-2 N protein antibody based on Ag nanoparticles with ultrathin Au shell assembled onto FeAnalytical and bioanalytical chemistry · 2023Article
- Rapid determination of SARS-CoV-2 nucleocapsid proteins based on 2D/2D MXene/P-BiOCl/Ru(bpy)Analytica chimica acta · 2022Article
- An outlook on potential protein targets of COVID-19 as a druggable site.Molecular biology reports · 2022Review
- Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies.Scientific reports · 2022Article
- Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.Microbiology spectrum · 2022Article
- Recent advances in immunoassay technologies for the detection of human coronavirus infections.Frontiers in cellular and infection microbiology · 2022Review
- Serological assessment of SARS-CoV-2 infection during the first wave of the pandemic in Louisville Kentucky.Scientific reports · 2021Article
- Article
- Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice.Scientific reports · 2021Article
- SARS-CoV-2: Insights into its structural intricacies and functional aspects for drug and vaccine development.International journal of biological macromolecules · 2021Review
- Development of a Nucleocapsid Protein-Based ELISA for Detection of Human IgM and IgG Antibodies to SARS-CoV-2.ACS omega · 2021Article
- Structural insights into SARS-CoV-2 proteins.Journal of molecular biology · 2021Review
- Manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for COVID-19 disease.Informatics in medicine unlocked · 2021Article
- Genomic Variations in the Structural Proteins of SARS-CoV-2 and Their Deleterious Impact on Pathogenesis: A Comparative Genomics Approach.Frontiers in cellular and infection microbiology · 2021Article
- Identification and molecular characterization of mutations in nucleocapsid phosphoprotein of SARS-CoV-2.PeerJ · 2021Article
- Structure and Function of Major SARS-CoV-2 and SARS-CoV Proteins.Bioinformatics and biology insights · 2021Review
- Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography.Frontiers in immunology · 2021Article
- Neutralizing antibodies mediate virus-immune pathology of COVID-19.Medical hypotheses · 2020Article
- Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19).Microbial pathogenesis · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome-coronavirus (SARS-CoV) causes an infectious disease through respiratory route. Diagnosing the disease effectively and accurately at early stage is essential for preventing the disease transmission and performing antiviral treatment. In this study, we raised monoclonal antibodies (mAbs) against the nucleocapsid (N) protein of SARS-CoV and mapped epitopes by using different truncated N protein fragments. The mapping of those epitopes was valuable for constructing pair-Abs used in serological diagnosis. The results showed that all of the six raised mAbs were divided into two groups recognizing the region of amino acids 249-317 (A group) or 317-395 (B group). This region spanning amino acids 249-395 contains predominant B cell epitopes located at the C-terminus of N protein. One pair-Abs, consisting of N protein-specific rabbit polyclonal antibody and SARS-CoV N protein-specific mAb, was selected to construct a sandwich ELISA-kit. The kit was able to specifically detect SARS-CoV N proteins in serum samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.